Eliot F. Battle, MD, cofounder and CEO of Cultura Dermatology & Laser Center in Washington, DC, and cochair of Skin of Color ...

Despite expanding treatment options for rare glomerular diseases such as immunoglobulin A nephropathy (IgAN) and focal ...

Adults and adolescents with alopecia areata had nearly 8 times higher odds of near-complete scalp hair regrowth on an oral ...

The Ambulatory Specialty Model (ASM) has the potential to reduce chronic disease costs by holding specialists accountable for ...

Under this rule, CMS opted for the term SRP as opposed to gender-affirming care because the latter "inaccurately describes ...

SGLT2 inhibitors have outgrown their diabetes-only label, and formulary teams that still price them that way are missing the bigger cardiorenal picture entirely.

Follitropin delta (Rekovelle; Ferring), a recombinant follicle-stimulating hormone produced in a human cell line, achieved cumulative ongoing pregnancy rates of 64.0% in patients ...

Although zidesamtinib (Jideytro; GSK) was designed to be better tolerated than other ROS1 inhibitors, it can still cause adverse effects that require monitoring, and questions remain about how best to ...

This indicates that rusfertide works for patients broadly rather than only for a subset, he explained. For durability, ...

D’Amico concluded that remigromig is the first biologic with a novel mechanism of action that demonstrated a noninferior ...

Medicare beneficiaries using lower-priced negotiated drugs experienced out-of-pocket savings under the Medicare Drug Price ...

Michael Mina, MD, PhD, of Invivyd explains how a few amino acid changes let VYD2311 move from IV to a single IM shot that ...